CN113355375B - Method for synthesizing B vitamins by fermenting lactobacillus paracasei K56 and application - Google Patents
Method for synthesizing B vitamins by fermenting lactobacillus paracasei K56 and application Download PDFInfo
- Publication number
- CN113355375B CN113355375B CN202011355562.XA CN202011355562A CN113355375B CN 113355375 B CN113355375 B CN 113355375B CN 202011355562 A CN202011355562 A CN 202011355562A CN 113355375 B CN113355375 B CN 113355375B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- fermentation
- vitamins
- lactobacillus paracasei
- milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000019156 vitamin B Nutrition 0.000 title claims abstract description 106
- 239000011720 vitamin B Substances 0.000 title claims abstract description 106
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims abstract description 80
- 230000004151 fermentation Effects 0.000 claims abstract description 80
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 8
- 241000218587 Lactobacillus paracasei subsp. paracasei Species 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 65
- 239000006228 supernatant Substances 0.000 claims description 29
- 235000013336 milk Nutrition 0.000 claims description 27
- 239000008267 milk Substances 0.000 claims description 27
- 210000004080 milk Anatomy 0.000 claims description 27
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 17
- 239000000758 substrate Substances 0.000 claims description 15
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 14
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims description 14
- 229940108924 conjugated linoleic acid Drugs 0.000 claims description 14
- 235000015140 cultured milk Nutrition 0.000 claims description 14
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 14
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 12
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 claims description 3
- 235000020122 reconstituted milk Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 17
- 235000019152 folic acid Nutrition 0.000 description 9
- 239000011724 folic acid Substances 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 9
- 235000018291 probiotics Nutrition 0.000 description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229960000304 folic acid Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000008939 whole milk Nutrition 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000020124 milk-based beverage Nutrition 0.000 description 3
- 235000020185 raw untreated milk Nutrition 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 208000007642 Vitamin B Deficiency Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 235000020121 low-fat milk Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010009260 Cleft lip and palate Diseases 0.000 description 1
- 241000222680 Collybia Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010042727 Swollen tongue Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000016653 cleft lip/palate Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000214 effect on organisms Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 feed Substances 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000009438 liyan Substances 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P25/00—Preparation of compounds containing alloxazine or isoalloxazine nucleus, e.g. riboflavin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a method for synthesizing B vitamins by fermenting lactobacillus paracasei K56 and application thereof. The invention firstly provides a method for synthesizing B vitamins by fermenting Lactobacillus paracasei (Lactobacillus paracasei subsp. Paracasei) K56, which comprises the following steps: the fermentation product containing B vitamins is prepared by fermenting lactobacillus paracasei CGMCC No.15139 or DSM 27447. The research of the invention finds that the lactobacillus paracasei strain can be used for the production and application of foods, daily chemicals, feeds or medicines and the like rich in B vitamins.
Description
Technical Field
The invention relates to the technical field of microbial fermentation, in particular to a method for synthesizing B vitamins by fermenting Lactobacillus paracasei (Lactobacillus paracasei subsp. Paracasei) K56 (with the preservation number of CGMCC No.15139 or DSM 27447) and related application.
Background
The B vitamins are also called B vitamins (also called vitamin B, vitamin B group or vitamin B complex group), and are classified as "families" because of 8 types in total. The B vitamins are water-soluble vitamins which are indispensable for maintaining the normal functions and metabolic activities of human bodies, and can be quickly consumed in the human bodies in the tense life and working pressure, improper dietary habits or due to the use of certain specific medicines and the property of dissolving the B vitamins in water. The supplement of vitamin B can relieve emotion. Moreover, according to research reports, the B vitamins can help to maintain the functions of the heart and the nervous system, maintain the health of the digestive system and the skin, participate in energy metabolism, enhance physical strength, tonify and strengthen the body. If vitamin B is absent, cell function is immediately reduced, and metabolic disorder is caused, at which the human body suffers from malaise and inappetence. Furthermore, excessive drinking and the like cause liver damage, which is concurrent with vitamin B deficiency in many cases.
The B vitamins are widely present in rice bran, wheat bran, yeast, animal livers, coarse grain vegetables and other foods. Studies have shown that part of the B vitamins can be synthesized in the human gut.
Lactobacillus paracasei is a gram-positive facultative heterotrophic lactic acid bacterium commonly used in dairy fermentation and probiotics. Lactobacillus paracasei is commonly found in a variety of human habitats, such as the human intestinal tract and oral cavity, as well as silage and naturally fermented foods.
No relevant research report about the B vitamins produced by the fermentation of lactobacillus paracasei is found.
Disclosure of Invention
One object of the present invention is to provide a novel use of lactobacillus paracasei K56.
Lactobacillus paracasei (Lactobacillus paracasei subsp. Paracasei) K56 strain has been deposited in German Collection of Microorganisms and Cell Cultures (German Collection of Microorganisms and Cell Cultures) on 27.6.2013 under accession number DSM27447; in addition, lactobacillus paracasei (Lactobacillus paracasei subsp. Paracasei) K56 strain has also been stored in China General Microbiological Culture Collection Center (CGMCC) with the Collection number of CGMCC No.15139 in 29.12 months and 29.2017.
The invention discovers that the Lactobacillus paracasei (Lactobacillus paracasei subsp. Paracasei) K56 takes the material liquid (milk substrate) mainly containing milk components as the fermentation substrate, and the fermentation product has high yield of B vitamins (containing vitamin B) 1 Vitamin B 2 Vitamin B 3 Vitamin B 6 Vitamin B 9 ) Of the cell.
Thus, in one aspect, the present invention provides a method for the fermentative synthesis of B vitamins from Lactobacillus paracasei (Lactobacillus paracasei subsp. Paracasei), comprising: the fermentation product containing B vitamins is prepared by fermenting lactobacillus paracasei CGMCC No.15139 or DSM 27447.
According to a particular embodiment of the invention, the method of the invention further comprises: extracting purified B vitamins from the supernatant of the fermentation product.
According to a specific embodiment of the present invention, the B vitamins include vitamin B 1 Vitamin B 2 Vitamin B 3 Vitamin B 6 And vitamin B 9 One or more of (a).
According to a specific embodiment of the present invention, the B vitamins include vitamin B 1 Vitamin B 3 And/or vitamin B 6 。
According to a particular embodiment of the invention, the fermentation substrate used in the fermentation may be an emulsion. Preferably, the milk may be raw milk or reconstituted milk, and may be whole milk, low fat milk or skim milk. The emulsion may optionally contain 5% to 10% sucrose.
According to a particular embodiment of the invention, the fermentation conditions are: fermenting for 1-7 days at 35-45 ℃.
According to a specific embodiment of the invention, lactobacillus paracasei is inoculated in the fermentation substrate in the form of seed liquid, with an inoculation amount of 2% to 5%. The preparation of the seed liquid may be carried out according to conventional techniques in the field of probiotics.
According to the specific embodiment of the present invention, the milk substrate used as the fermentation substrate of lactobacillus paracasei K56 in the present invention may be milk (whole milk, low-fat milk or skim milk) with milk content of more than 80%, wherein auxiliary materials such as sweetener, stabilizer and the like may be optionally added according to the need, such as fermentation substrate commonly used in the preparation of fermented milk or milk beverage, and the milk substrate fermented by lactobacillus paracasei K56 of the present invention can achieve the effect of high yield of B vitamins, and the fermentation product is particularly rich in vitamin B 1 Vitamin B 2 Vitamin B 3 Vitamin B 6 Vitamin B 9 。
Vitamin B 1 The content in milk is 0.3 mg/L on average. Vitamin B in milk 1 Is not completely from feed, and can be synthesized by microorganism in rumen of milk cow, so that sour milk fermented by lactic acid bacteria is superior to normalTonghua milk vitamin B 1 The content is increased by about 30 percent. Children less than one week in age need vitamin B daily 1 5-10mg. If vitamin B is deficient 1 It can cause anorexia, slow growth, damage of nervous system activity, polyneuritis, milk regurgitation or constipation, dyspepsia, greenish stool, pale complexion, inappetence, muscle relaxation, frequent crying, and weight loss in children. According to some embodiments of the invention, lactobacillus paracasei K56 ferments vitamin B in the emulsion 1 The content can reach 30-70 mu g/mL. The yogurt product fermented by K56 is taken 100 mL/day, and can be supplemented with VB for human body intake 1 。
Vitamin B 2 In human milk, the content of vitamin B in cow milk is not high 2 The content can reach 1-2mg/L. The children are recommended to take 1-3mg of vitamin B every day. If vitamin B2 is lacked, the children will suffer from growth retardation, anorexia, inflammation of mouth corners and lips, red and swollen tongue, malnutrition, and asthenia. According to some embodiments of the invention, lactobacillus paracasei K56 ferments vitamin B in the emulsion 2 The content can reach 2.8-3 mug/mL.
Vitamin B 3 (nicotinic acid) is recommended to be taken by adults at 13-19mg per day (dietary guidelines of Chinese residents), 20mg per day is recommended for pregnant women, and 22mg per day is recommended for pregnant women in lactation. Vitamin B 3 It is mainly contained in livestock meat, fish and poultry, and plant foods such as mushroom, asparagus, sunflower seed, peanut, beans and grains. Vitamin B in ordinary yoghurt 3 Is present in an amount of about 0.2mg/100g. According to some embodiments of the invention, lactobacillus paracasei K56 ferments vitamin B in the emulsion 3 50-80 mug/mL, which is far higher than the content in the common yoghourt.
Vitamin B 6 Also known as pyridoxine, which includes pyridoxine, pyridoxal and pyridoxamine, exists as phosphate esters in vivo, and is a water-soluble vitamin. Vitamin B 6 The functionality involves a number of aspects including: participating in protein synthesis and catabolism and participating in all amino acid metabolism; participating in gluconeogenesis and UFA generationMetabolism, associated with the metabolism of glycogen, sphingomyelin, and steroids; participate in the synthesis of certain neuromediators (5-hydroxytryptamine, taurine, dopamine, norepinephrine and gamma-aminobutyric acid); involving nucleic acid and DNA synthesis, and lacking vitamin B 6 DNA synthesis is impaired, a process which is important for maintaining proper immune function. Papastoyianidis et al (2006) use commercial ferments YO-1, YO-2 to ferment at 42 ℃ for 3.5h, then store for 1.5h in cold storage, detect vitamin B 6 The content of (A) is 1.37mg/kg and 1.50mg/kg respectively; vitamin B after fermentation assisted by Bifidobacterium BB-12 and Lactobacillus acidophilus LA-5 6 The contents of (A) are 1.37mg/kg and 1.31mg/kg, respectively. According to some embodiments of the invention, lactobacillus paracasei K56 ferments vitamin B in the emulsion 6 The content is 8-20 mug/mL.
Vitamin B 9 The content of the (folic acid) in the milk is generally 40 +/-10.00 mu g/L, and the content of the (folic acid) in the common yoghourt is 80 +/-20.00 mu g/L. Vitamin B 9 The main effects on organisms are as follows: are involved in the metabolism of genetic material and proteins; influence animal reproductive performance; affecting secretion of animal pancreas; promoting the growth of animals; improving immunity of organism. Vitamin B 9 As one of the essential vitamins for the growth and reproduction of body cells, the deficiency can affect the normal physiological activities of human bodies. Many reports in the literature of vitamin B deficiency 9 Has direct relation with diseases such as neural tube deformity, megaloblastic anemia, cleft lip and palate, depression, tumor and the like. In general, normal humans require vitamin B 9 The amount of the medicine is 100-200 mu g/d, and the recommended amount of the world health organization is as follows: adult 200 ug/d, pregnant woman and lactating mother 400 ug/d. The latest folic acid consumption standard of the FDA is as follows: between 25 and 50 years old (male) 240 μ g/d; 190 μ g/d between 25 and 50 years old (female); the concentration of the extract is 400 mug/d for the nannie and the pregnant woman; the infant is 200-400 mug/d. According to some embodiments of the invention, lactobacillus paracasei K56 ferments vitamin B in the emulsion 9 The content of (b) is 1.6-1.8 mu g/mL.
Therefore, in another aspect, the invention also provides the application of the lactobacillus paracasei in the preparation of the composition rich in B vitamins by fermentation, wherein the fermentation product rich in B vitamins is prepared by utilizing the fermentation of the lactobacillus paracasei with CGMCC No.15139 or DSM 27447.
According to a particular embodiment of the invention, the lactobacillus paracasei of the invention is used in the fermentative preparation of a composition enriched in B vitamins, which may be a food composition, a daily chemical composition or a pharmaceutical composition. Specifically, the fermentation product obtained by fermenting the milk substrate with lactobacillus paracasei K56 of the present invention can be directly used as a food (e.g., fermented milk, milk drink, milk powder, solid drink, etc.), a daily chemical (e.g., cosmetics), a feed (including pet food or probiotic products for livestock), a drug, etc., or further used for preparing such food, daily chemical, feed, or drug products. The process for preparing food, daily chemical, feed or pharmaceutical products from the fermentation product can be carried out with reference to the prior art in the field.
In a particular embodiment of the invention, the B vitamin containing fermentation product of the invention is used as or further for the preparation of a food product, preferably a fermented milk or fermented milk beverage. The emulsion used as a fermentation substrate may further comprise other materials commonly used in fermented milk or fermented milk drinks, such as appropriate amounts of sweeteners, stabilizers, nutritional additives, and the like.
According to a particular embodiment of the invention, the fermented milk matrix of lactobacillus paracasei of the invention results in a fermentation product containing B vitamins which is also enriched in conjugated linoleic acid and/or gamma-aminobutyric acid. Therefore, the invention also provides the application of the lactobacillus paracasei K56 in the preparation of a composition rich in conjugated linoleic acid and/or gamma-aminobutyric acid through fermentation. In the composition, the conjugated linoleic acid and/or the gamma-aminobutyric acid are mainly generated by fermenting the lactobacillus paracasei.
In conclusion, the invention provides the new application of the lactobacillus paracasei K56, and the invention discovers that the single-strain fermented milk substrate of the strain has good vitamin B-containing synthetic vitamin B 1 Vitamin B 2 Vitamin B 3 Vitamin B 6 Vitamin B 9 The ability of the cell to perform. The Lactobacillus paracasei K56 strain can be used for enriching B vitaminsFood, daily chemical products, feed or medicine, etc.
Detailed Description
For a more clear understanding of the technical features, objects and advantages of the present invention, reference is now made to the following detailed description taken in conjunction with the accompanying specific embodiments, and the technical solutions of the present invention are described, it being understood that these examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention. In the examples, each raw reagent material is commercially available, and the experimental method not specifying the specific conditions is a conventional method and a conventional condition well known in the art, or a condition recommended by an instrument manufacturer.
Example 1: production of B vitamins from Lactobacillus paracasei fermented milk
1. Experimental strains
The lactobacillus paracasei K56 (CGMCC No. 15139) used in the technical proposal of the invention;
control strain 1: lactobacillus paracasei strain l.casei 431;
control strain 2: the commercial strain Lactobacillus paracasei LPC-37.
2. Activation of strains and liquid culture of seeds
(1) Strain activation: activating lactobacillus paracasei by using MRS culture medium, taking the strain growing to logarithmic phase, and preserving glycerol tubes for later use. Wherein, MRS culture medium (g/L): 10.0g of peptone; 5.0g of yeast extract; 20.0g of glucose; 5.0g of anhydrous sodium acetate; 2.0g of citric acid dihydroamine; tween-80.0 mL; dipotassium phosphate 2.0g; magnesium sulfate heptahydrate 0.2g; 0.05g of manganese sulfate; 10.0g of beef extract; 15g to 20g of agar.
(2) Determination of growth dynamics of strains
Dissolving 12% whole milk powder and 6% white sugar in water at normal temperature, sterilizing at 95 deg.C for 5min, cooling to 36 + -1 deg.C, inoculating strain as milk matrix, fermenting and culturing for 120h, sampling at different fermentation time periods, and measuring viable count and pH value.
And (3) detecting the viable count: after mixing 25ml of the sample with 75ml of physiological saline uniformly, counting by a plate dilution method.
And (3) acidity detection: the sample pH was measured using a pH meter and recorded. Taking 10g of the fermented dairy product, adding 2 drops of phenolphthalein solution, mixing uniformly, and titrating 0.1M standard NaOH solution to pink. The calculation formula of the titration acidity is as follows:
°T=C×V×100/(m×0.1)。
the results of the measurements are shown in tables 1 and 2, respectively.
TABLE 1 colony count of Lactobacillus paracasei in milk matrix for different fermentation times
From the analysis of the test data, the pH value of K56 fermentation is rapidly increased after 28h, and then is reduced to be stable. The viable count of the control strain 1 and the control strain 2 increased rapidly after 36 hours, and then decreased steadily. The analysis of the K56, the control strain 1 and the control strain 2 shows that p is more than 0.05, and no significant difference exists; control strain 1 and control strain 2 analyzed p >0.05 with no significant difference. Wherein the blank group is the milk matrix without the addition of bacteria liquid.
TABLE 2 pH determination of Lactobacillus paracasei in milk substrates for different fermentation times
From the analysis of the test data, K56, the control strain 1 and the control strain 2 gradually decrease within 12-36 h. The p of K56 is less than 0.01 when being analyzed by a control strain 2, and the difference is very obvious; k56 was >0.05 as analyzed for p with control strain 1, with no significant difference; control strain 1 and control strain 2 analyzed p >0.05 with no significant difference. The presence of non-killed micro-organisms in the blank resulted in milk spoilage and a decrease in pH due to temperature. Wherein the blank group is an emulsion matrix without added bacteria liquid.
(3) Preparation of strain seed liquid: dissolving 12% whole milk powder and 6% white sugar in water at normal temperature, sterilizing at 95 deg.C for 5min, cooling to 36 + -1 deg.C, inoculating strain, fermenting at 36 + -1 deg.C for 48 + -2 h, and prolonging to 72 + -2 h to obtain seed liquid.
3. Synthesis of B vitamins from lactobacillus paracasei fermented milk
Preparing fermented milk: adding sucrose accounting for 6.5% of the total weight of raw milk into raw milk, stirring, heating to 95 ℃, sterilizing for 5min, cooling the sterilized emulsion to 37 ℃, respectively adding various bacterial seed liquids (the inoculation amount of lactobacillus paracasei K56 is 3%, the inoculation amount of the control bacteria is equivalent to K56 according to the conversion of viable count), respectively fermenting each sample at 37 ℃ for 24, 48, 72, 96 and 120h, centrifuging the fermented emulsion at 8000r/min for 15min, collecting fermented supernatant, filtering through a 0.22 mu m filter membrane, and measuring the content of B vitamins in the filtrate.
The content of B vitamins is determined by high performance liquid chromatography, and the specific operation conditions refer to HPLC detection of water-soluble vitamins (Liyan, food research and development, 2018) in Collybia nigricans.
Blank milk base (without added probiotics) was used as a control, and blank control supernatant could not be obtained by centrifugation due to the inability to curd during the same fermentation time. Thus, the following data are the directly measured vitamin content in the supernatant of the fermentation broth, without subtracting the vitamin content in the blank milk matrix.
(1) Vitamin B in fermentation samples 1 In an amount of
Vitamin B in probiotic fermentation supernatant with different fermentation times 1 See table 3 for the contents of (d).
TABLE 3 fermentation supernatant vitamin B 1 In an amount of
From the analysis of the above test data, it can be seen that vitamin B is present in the fermentation supernatant of each strain 1 The content shows a clear rising trend along with the time. Differences were found between K56, control strain 1, and control strain 2, but were not significant.
(2) Fermentation sample vitamin B 2 In a content of
Vitamin B in probiotic fermentation supernatant with different fermentation times 2 See table 4 for the content of (d).
TABLE 4 vitamin B in fermentation supernatants 2 In a content of
From the analysis of the above test data, it can be seen that each strain produces vitamin B in the supernatant of the fermentation at different times 2 The contents are all close and the difference is not significant. Wherein vitamin B in the supernatant in the first 72h 2 The content shows a clear ascending trend, and the content is basically unchanged after 48 h.
(3) Fermentation sample vitamin B 3 In a content of
Vitamin B in probiotic fermentation supernatant with different fermentation times 3 See table 5 for the content of (d).
TABLE 5 vitamin B in fermentation supernatants 3 In a content of
The analysis of the test data shows that the vitamin B in the K56 120h fermentation supernatant 3 The content was about 1.4 times that of the control strain 2. Vitamin B in fermentation supernatant of each strain 3 The content showed a clear ascending trend with time, and the ascending trend of the control strain 2 was relatively slow. Vitamin B in supernatant of K56 and control Strain 1 when fermented for 120h 3 The content difference is obvious (p is less than 0.05). K56 and vitamin B in the fermentation supernatant of control Strain 2 3 The content difference is very obvious (p is less than 0.01).
(4) Fermentation sample vitamin B 6 In an amount of
Vitamin B in probiotic fermentation supernatant with different fermentation times 6 See table 6 for the contents of (d).
TABLE 6 HairVitamin B in fermentation supernatant 6 In a content of
The analysis of the test data shows that the vitamin B in the K56 120h fermentation supernatant 6 The content was about 1.4 times that of the control strain 2. Vitamin B in fermentation supernatant of each strain 6 The content showed a clear rising trend with time, the rising trend of the control strain 2 was relatively slow. Vitamin B in supernatant after 72h fermentation of K56 and control Strain 1 6 The content difference is obvious (p is less than 0.05). Vitamin B in supernatant after 72h fermentation of K56 and control Strain 2 6 The content difference is obvious (p is less than 0.05).
(5) Fermentation sample vitamin B 9 In a content of
Vitamin B in probiotic fermentation supernatant with different fermentation times 9 See table 7 for the contents of (d).
TABLE 7 vitamin B 9 In an amount of
From the analysis of the above test data, it can be seen that vitamin B is present in the fermentation supernatant of each strain 9 The content of vitamin B is substantially constant with time 9 The contents were all at a lower level.
According to the experimental result of the viable count of each strain, the lactobacillus paracasei reaches the maximum value of the viable count within about 48 hours, namely the stable period, and the viable counts are kept unchanged after 48 hours. After 24h fermentation, fermentation supernatant can not be obtained to detect the content of folic acid, but folic acid is supposed to be metabolized and generated in the process of strain growth. There was no significant difference in the folate content over time during the subsequent fermentation time, a possible reason: the folic acid content reaches the maximum value in the stable growth period (48 h) of the strain, and the thallus is aged and the folic acid synthesis amount is reduced along with the continuous metabolism of the strain; the influence of environmental factors such as light, heat, temperature and the like on the folic acid content in the experimental process.
(6) Content of Conjugated Linoleic Acid (CLA) and gamma-aminobutyric acid in fermentation sample
In the invention, the beneficial substances such as Conjugated Linoleic Acid (CLA) and gamma-aminobutyric acid are generated in the K56 fermented milk. See tables 8 and 9 for relevant test results. Wherein, the content determination method of the conjugated linoleic acid is based on a gas chromatography NY/T1671-2008 for determining the content of the Conjugated Linoleic Acid (CLA) in milk and dairy products; the content determination method of the gamma-aminobutyric acid is based on QB/T4587-2013 gamma-aminobutyric acid.
TABLE 8 content of conjugated linoleic acid in K56 fermentation supernatant
TABLE 9 content of gamma-aminobutyric acid in fermentation supernatant
Example 2 fermentation of Lactobacillus paracasei K56 milk beverage enriched in vitamin B group
Heating fresh milk to more than 50 ℃, adding 6% of white granulated sugar, stirring until the white granulated sugar is completely dissolved, preheating to 60-65 ℃, homogenizing under 20Mpa pressure, carrying out heat treatment for 5-8 minutes at about 90 ℃, cooling to 37 ℃, and inoculating lactobacillus paracasei K56 seed liquid with the inoculation amount of 2-3%. Fermenting at 37 deg.C for 72-96 h. Diluting the fermented product with sterilized and cooled mixture of water, syrup, emulsion stabilizer, etc. by 2-4 times, and making into directly drinkable lactobacillus beverage. The lactobacillus beverage has sour and sweet taste, good flavor, and high vitamin B content 1 Vitamin B 3 Vitamin B 6 Conjugated linoleic acid and gamma-aminobutyric acid content.
Claims (10)
1. A method for synthesizing B vitamins by fermenting Lactobacillus paracasei (Lactobacillus paracasei subsp. Paracasei), which comprises the following steps: the lactobacillus paracasei CGMCC No.15139 or DSM27447 is used for fermentation to prepare the product containingA fermentation product with B vitamins; wherein, the fermentation substrate used in the fermentation is emulsion, and the emulsion is fresh milk or reconstituted milk; the B vitamins are selected from vitamin B 1 Vitamin B 2 Vitamin B 3 Vitamin B 6 And vitamin B 9 One or more of (a).
2. The method of claim 1, further comprising: extracting purified B vitamins from the supernatant of the fermentation product.
3. The method of claim 1 wherein the B vitamins are vitamin B 1 Vitamin B 3 And/or vitamin B 6 。
4. The method of claim 1, wherein the emulsion comprises 5% to 10% sucrose.
5. The process according to claim 1 or 4, wherein the fermentation is carried out under the following conditions: fermenting for 1-7 days at 35-45 ℃.
6. The method according to claim 1 or 4, wherein the Lactobacillus paracasei is inoculated in the fermentation substrate in the form of seed liquid, in an amount of 2% to 5%.
7. The application of the lactobacillus paracasei in the preparation of the composition rich in B vitamins by fermentation is characterized in that the lactobacillus paracasei is fermented by CGMCC No.15139 or DSM27447 to prepare a fermentation product rich in B vitamins; the obtained fermentation product containing the B vitamins is used as or further used for preparing food, daily chemicals, feed or medicines; wherein, the fermentation substrate used in the fermentation is emulsion, and the emulsion is fresh milk or reconstituted milk; the B vitamins are selected from vitamin B 1 Vitamin B 2 Vitamin B 3 Vitamin B 6 And vitamin B 9 One or more of (a).
8. Use according to claim 7, wherein the food product is a fermented milk, a fermented milk drink or a milk powder.
9. Use according to claim 7, wherein the food product is a solid beverage.
10. Use according to claim 7 or 8 or 9, wherein the composition is further enriched in conjugated linoleic acid and/or gamma-aminobutyric acid, the conjugated linoleic acid and/or gamma-aminobutyric acid being produced by fermentation of the lactobacillus paracasei.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011355562.XA CN113355375B (en) | 2020-11-26 | 2020-11-26 | Method for synthesizing B vitamins by fermenting lactobacillus paracasei K56 and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011355562.XA CN113355375B (en) | 2020-11-26 | 2020-11-26 | Method for synthesizing B vitamins by fermenting lactobacillus paracasei K56 and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113355375A CN113355375A (en) | 2021-09-07 |
CN113355375B true CN113355375B (en) | 2022-11-22 |
Family
ID=77524555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011355562.XA Active CN113355375B (en) | 2020-11-26 | 2020-11-26 | Method for synthesizing B vitamins by fermenting lactobacillus paracasei K56 and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113355375B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117904245A (en) * | 2024-01-12 | 2024-04-19 | 广东燕塘乳业股份有限公司 | Vitamin B can be fermented and synthesized2Synbiotic combination of (C) and fermentation method and application thereof |
CN117904230A (en) * | 2024-01-12 | 2024-04-19 | 广东燕塘乳业股份有限公司 | Vitamin B can be fermented and synthesized1Synbiotic combination of (C) and fermentation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUB20152376A1 (en) * | 2015-07-07 | 2017-01-09 | Alfasigma Spa | LACTOBACILLUS PARACASEI FOR THE PRODUCTION OF CONJUGATED LINOLEIC ACID, NUTRITIONAL AND PHARMACEUTICAL PREPARATIONS THAT INCLUDE IT AND THEIR USE |
CN105076402A (en) * | 2015-09-25 | 2015-11-25 | 齐齐哈尔医学院 | Method for preparing health yogurt rich in natural folic acid |
KR101778260B1 (en) * | 2016-01-25 | 2017-09-13 | 충남대학교산학협력단 | Preparation Method for Kimchi with High GABA Content |
TWI592487B (en) * | 2016-10-05 | 2017-07-21 | 益福生醫股份有限公司 | Novel lactobacillus paracasei subsp. paracasei k56 |
CN110301480A (en) * | 2018-03-20 | 2019-10-08 | 内蒙古蒙牛乳业(集团)股份有限公司 | Milk-contained drink and preparation method thereof |
CN110959865B (en) * | 2018-09-30 | 2021-07-09 | 内蒙古伊利实业集团股份有限公司 | New application of lactobacillus paracasei K56 capable of adjusting gastrointestinal flora balance |
CN110882280B (en) * | 2019-06-27 | 2023-03-24 | 内蒙古伊利实业集团股份有限公司 | Novel application of lactobacillus paracasei K56 |
CN111733105B (en) * | 2020-07-03 | 2022-05-31 | 上海商学院 | Fermentation agent for improving content of gamma-aminobutyric acid in fermented milk and preparation method of fermented milk rich in gamma-aminobutyric acid |
-
2020
- 2020-11-26 CN CN202011355562.XA patent/CN113355375B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113355375A (en) | 2021-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4187321A (en) | Method for producing foods and drinks containing bifidobacteria | |
CN110923166A (en) | Bifidobacterium animalis subsp lactis JMCC0025, and separation and purification method and application thereof | |
CN101939441B (en) | Increased folate production levels in lactobacillus fermenting melon juice | |
CN116024130B (en) | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof | |
CN102191202B (en) | High-density culture method for lactic acid bacteria | |
CN113355376A (en) | Method for synthesizing B vitamins by fermenting bifidobacterium lactis BL-99 and application | |
CN1915042A (en) | Method for producing zymophyte agent in direct input type for yoghourt | |
CA2811390C (en) | Method of production of fermented, pro-healthy, cereal beverages | |
AU2017287988B2 (en) | Renal anemia ameliorating composition | |
CN113355375B (en) | Method for synthesizing B vitamins by fermenting lactobacillus paracasei K56 and application | |
AU2017287989B2 (en) | Composition for use in improvement of nutritional state | |
CN106460029A (en) | Lactic acid bacterium for suppressing purine absorption and use for same | |
CN116676226B (en) | Lactobacillus plantarum LP-28 for relieving anxiety, yoghourt and application | |
WO2016080371A1 (en) | Lactic acid bacterium having purine body uptake ability, and use thereof | |
CN113755370B (en) | Application of lactobacillus acidophilus LA85 in preparation of hypolipidemic drugs or health-care foods | |
CN113355374B (en) | Method for synthesizing B vitamins by fermenting lactobacillus paracasei ET-22 and application | |
CN110250270B (en) | Method for improving fermented milk folic acid content by using lactobacillus plantarum | |
CN110982731A (en) | Space-induced lactobacillus plantarum ST20-71 with probiotic characteristics and application thereof | |
CN107083342B (en) | Probiotic symbiont, culture method and application | |
EP3479836A1 (en) | Cartilage regeneration facilitating composition | |
CN113908177A (en) | BF839, bifidobacterium and facultative probiotic culture solution and preparation thereof | |
CN108464509B (en) | Application of novel lactobacillus fermentum in food field | |
CN110897166A (en) | Edible composition containing probiotics and casein phosphopeptides and having digestion promoting effect | |
CN111213792A (en) | Biological fermentation feed for improving piglet anemia and preparation method thereof | |
CN117660246B (en) | Lactococcus lactis subspecies S28 for producing metabolic enzymes and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |